|
|
Post by prcgorman2 on Dec 7, 2020 20:55:05 GMT -5
My corporate finance professor taught that the street does not generally favor mergers and acquisitions for the acquiring company. He said the sentiment is based on concern management is feathering their nest with more things to be managing. I never quite believed that explanation although it might be perfectly valid, and in any case I assumed he was just offering “common wisdom” on observed statistics. In the case of MNKD and the qrums, I assume it was for what Matt said, but I do assume years of development and goofing around with the FDA. You know, our black box friends. Have they gotten around to approving any COVID vaccines yet? I guess they must think the FDA-equivalent in Great Britain was capricious when they approved Pfizer’s application.
Anyway, I expect qrm is good for the longer term and I hope they are.
|
|
|
|
Post by georgethenight2 on Dec 7, 2020 22:58:33 GMT -5
I am hoping this is not the only "exciting" event happening in December.
|
|
|
|
Post by sweedee79 on Dec 7, 2020 23:22:25 GMT -5
It certainly sounds good, but we were already concerned there may be dilution before this acquisition... Now what?
|
|
|
|
Post by letitride on Dec 8, 2020 7:28:32 GMT -5
As I check the qrumpharma website I see under the technology tab it says will be updated soon. I do believe tecnosphere is it. Looks like it went from a possible partnership to M&A. I also see they received there orphan drug designation in august 2018 from the FDA and a year later from the EMA. In july 2017 they received a grant from the CF foundation along with funding from unspecified source to carry them thru to July of 2019. Looks like funding got thin for the past year probably providing for the current M&A. The ODD from the FDA and EMA could be huge if exploited quickly in the right way in my opinion.
|
|
|
|
Post by tarheelblue004 on Dec 8, 2020 11:19:46 GMT -5
My simple takeaway is that we've moved from bleeding cash to being fiscally stable enough to purchase another company! For a new investor, recent press releases tout partners and acquisitions vs. gloom and doom / bankruptcy. For those who believe MannKind price does not reflect the company's value due to the amount of risk priced in, every piece of evidence showing the company is stronger than ever should help.
|
|
|
|
Post by harryx1 on Dec 8, 2020 11:33:03 GMT -5
So I believe after researching a bit, there could be 3 or more products that come out of this acquisition... From the purchase agreement... (1) if the total Adjusted Net Sales were $400,000,000 for a given Calendar Year, comprised of $225,000,000 from sales of Clofazimine Product, $150,000,000 from sales of Dry Powder Product and $25,000,000 from sales of Bedaquiline Product, then the Contingent Payment payable with respect to such Net Sales in such Calendar Year would be $5,500,000: ($350,000,000 x 1.5%) + ($25,000,000 x 1.0%); Here is a publication from QrumPharma and also believe that their minds changed about DPI once they understood Technosphere and it's benefits... www.mdpi.com/1999-4923/11/7/352/pdfAdded: In addition, The name Qrumpharma is derived from quorum sensing, in which colonies of bacteria can work together to be more successful than an individual. BioFilms are a big deal and help protect colonies of bacteria. Biofilms make certain colonies extremely hard to kill as the antibiotic cannot penetrate the biofilm to get to the organism itself. This would be a huge breakthrough if something was developed to breakdown that biofilm and then deliver the antibiotic to the bacteria. www.ncbi.nlm.nih.gov/pmc/articles/PMC3376616/ |
|
|
|
Post by radgray68 on Dec 8, 2020 12:28:07 GMT -5
Mike did say many times this year they were looking for "bolt-on" acquisitions and additional products to put into our sales bag. Well, here we go. Orphan lung focus, minimal time to rollout, utilizes(or will soon) our platform technology, costs only about a month's expenses to acquire, more talent coming to Mannkind. Yeah, you can say I'm on board.
|
|
|
|
Post by mango on Dec 8, 2020 18:37:17 GMT -5
So I believe after researching a bit, there could be 3 or more products that come out of this acquisition... From the purchase agreement... (1) if the total Adjusted Net Sales were $400,000,000 for a given Calendar Year, comprised of $225,000,000 from sales of Clofazimine Product, $150,000,000 from sales of Dry Powder Product and $25,000,000 from sales of Bedaquiline Product, then the Contingent Payment payable with respect to such Net Sales in such Calendar Year would be $5,500,000: ($350,000,000 x 1.5%) + ($25,000,000 x 1.0%); Here is a publication from QrumPharma and also believe that their minds changed about DPI once they understood Technosphere and it's benefits... www.mdpi.com/1999-4923/11/7/352/pdfAdded: In addition, The name Qrumpharma is derived from quorum sensing, in which colonies of bacteria can work together to be more successful than an individual. BioFilms are a big deal and help protect colonies of bacteria. Biofilms make certain colonies extremely hard to kill as the antibiotic cannot penetrate the biofilm to get to the organism itself. This would be a huge breakthrough if something was developed to breakdown that biofilm and then deliver the antibiotic to the bacteria. www.ncbi.nlm.nih.gov/pmc/articles/PMC3376616/Just to stir the pot a little more, sense we are on the subject of quorum sensing. Professor Raphael Mechoulam conducted an interesting experiment with a synthetic cannabinoid called, HU-210 on quorum sensing and different quorum sensing-regulated physiological processes in bacteria. Here’s a few studies using cannabinoids against quorum sensing. Second one is the Mechoulam study. Cannabigerol Prevents Quorum Sensing and Biofilm Formation of Vibrio harveyiwww.ncbi.nlm.nih.gov/pmc/articles/PMC7221000/ Effect of the synthetic cannabinoid HU-210 on quorum sensing and on the production of quorum sensing-mediated virulence factors by Vibrio harveyiwww.ncbi.nlm.nih.gov/pmc/articles/PMC4531395/ Cannabinoids infused mouthwash products are as effective as chlorhexidine on inhibition of total-culturable bacterial content in dental plaque sampleslink.springer.com/article/10.1186%2Fs42238-020-00027-z |
|
|
|
Post by falconquest on Dec 8, 2020 19:30:43 GMT -5
My simple takeaway is that we've moved from bleeding cash to being fiscally stable enough to purchase another company! For a new investor, recent press releases tout partners and acquisitions vs. gloom and doom / bankruptcy. For those who believe MannKind price does not reflect the company's value due to the amount of risk priced in, every piece of evidence showing the company is stronger than ever should help. When did this happen, last week? I'm not so sure about your "fiscally stable" label. To me this shows that Mike needs some other horse to ride other than Afrezza because he hasn't figured out how to sell it. We shall see how it turns out but I'm still from Missouri.....show me! |
|
|
|
Post by longliner on Dec 8, 2020 20:01:22 GMT -5
My simple takeaway is that we've moved from bleeding cash to being fiscally stable enough to purchase another company! For a new investor, recent press releases tout partners and acquisitions vs. gloom and doom / bankruptcy. For those who believe MannKind price does not reflect the company's value due to the amount of risk priced in, every piece of evidence showing the company is stronger than ever should help. When did this happen, last week? I'm not so sure about your "fiscally stable" label. To me this shows that Mike needs some other horse to ride other than Afrezza because he hasn't figured out how to sell it. We shall see how it turns out but I'm still from Missouri..... show me! By the time you are shown, hopefully your sideline will be less comfortable.  |
|
|
|
Post by tarheelblue004 on Dec 8, 2020 20:28:45 GMT -5
My simple takeaway is that we've moved from bleeding cash to being fiscally stable enough to purchase another company! For a new investor, recent press releases tout partners and acquisitions vs. gloom and doom / bankruptcy. For those who believe MannKind price does not reflect the company's value due to the amount of risk priced in, every piece of evidence showing the company is stronger than ever should help. When did this happen, last week? I'm not so sure about your "fiscally stable" label. To me this shows that Mike needs some other horse to ride other than Afrezza because he hasn't figured out how to sell it. We shall see how it turns out but I'm still from Missouri.....show me! If you’re asking if we could have purchased them a month or a year before we did, I couldn’t tell you that. I can tell you we are now an acquirer of inhaled products in R&D and a partner for commercialization of inhaled products. I do agree with your underlying point that Afrezza growth is far lower than desired and previously expected. But I also think it’s unfair (and a non-sequitur) to say that because we made an acquisition, we had to make the acquisition (vs. it being opportunistic). I view this as a medium term (3+ year) time to revenue. Not a replacement of Afrezza or Afrezza revenue, but a future growth driver if a product pans out. I can’t blame your Missouri attitude, especially on this company! My viewpoint does differ from yours. |
|
|
|
Post by falconquest on Dec 8, 2020 22:03:08 GMT -5
When did this happen, last week? I'm not so sure about your "fiscally stable" label. To me this shows that Mike needs some other horse to ride other than Afrezza because he hasn't figured out how to sell it. We shall see how it turns out but I'm still from Missouri.....show me! If you’re asking if we could have purchased them a month or a year before we did, I couldn’t tell you that. I can tell you we are now an acquirer of inhaled products in R&D and a partner for commercialization of inhaled products. I do agree with your underlying point that Afrezza growth is far lower than desired and previously expected. But I also think it’s unfair (and a non-sequitur) to say that because we made an acquisition, we had to make the acquisition (vs. it being opportunistic). I view this as a medium term (3+ year) time to revenue. Not a replacement of Afrezza or Afrezza revenue, but a future growth driver if a product pans out. I can’t blame your Missouri attitude, especially on this company! My viewpoint does differ from yours. I admit to being a bit cynical but so far Mike has managed the financials, signed some deals and now has acquired a new pipeline. I want to see him sell something. Generate some revenue! I'm in sales so this drives me nuts. |
|
|
|
Post by mytakeonit on Dec 9, 2020 1:08:12 GMT -5
And falcon ... have you acquired more shares that makes your post relevant?
But, that's mytakeonit
|
|
|
|
Post by prcgorman2 on Dec 9, 2020 7:56:34 GMT -5
If you’re asking if we could have purchased them a month or a year before we did, I couldn’t tell you that. I can tell you we are now an acquirer of inhaled products in R&D and a partner for commercialization of inhaled products. I do agree with your underlying point that Afrezza growth is far lower than desired and previously expected. But I also think it’s unfair (and a non-sequitur) to say that because we made an acquisition, we had to make the acquisition (vs. it being opportunistic). I view this as a medium term (3+ year) time to revenue. Not a replacement of Afrezza or Afrezza revenue, but a future growth driver if a product pans out. I can’t blame your Missouri attitude, especially on this company! My viewpoint does differ from yours. I admit to being a bit cynical but so far Mike has managed the financials, signed some deals and now has acquired a new pipeline. I want to see him sell something. Generate some revenue! I'm in sales so this drives me nuts. In sales? That tells more than being from Missouri. Are you in pharma sales by any chance? If so, you’re opinion just got a lot more interesting. How’s it going this year with the pandemic? A little challenging working virtually? Do you sell a suite of products, or just one? Do your customers have access to well-established and cheaper alternatives and can get financial assistance (aka incentive) to purchase those other products? How about the regulatory side of things? Are your products regulated? Have regulators placed warnings on the use of your product and restrictions about how it’s sold that your competitor’s alternatives do not? I could go on and on. I feel like I already have. One last question. Have I shown you what it is you aren’t thinking about? |
|
|
|
Post by MnkdWASmyRtrmntPlan on Dec 9, 2020 12:54:30 GMT -5
PC, your point is that Mike has a tough job. Falcon's point is that Falcon is not happy with the job that Mike has done so far. Falcon has been on this board as long as you and I have, and he knows the environment that Mike has worked in. Throughout all these years, we have all had our own opinions of Mike. My opinion of Mike is much different than yours, and much more like Falcon's. IMHO, MNKD needs more than anything else to become profitable already and I wish Mike would stay more focused on that. We have all had enough disappointment in this investment throughout all these years. Mike has proven that he does not have the capability that we have hoped for. I hope daily to read the news that Mike has taken a job with some other company. It has been an exhausting journey, but we are not really very far from that elusive point where red turns to black ... that magic hockey stick inflection point. PC, when you said "In sales? That tells more than being from Missouri", you attacked Falcon on his profession and his home. I respect your opinion, but that was a little uncalled for. I don’t want to see this board erupt again. Remember 2-3 years ago when our concern was whether MNKD would go bust? There was so much tension on this board then that posters were like a virtual version of the black lives matter rioters in Seattle. But now, along with this pandemic, and the polarizing world that our president has created, which has stressed us all into a big group-panic-attack, tensions have been way too stressful for us all. Christmas is too close, and MNKD is too close to profitability. We need to stay chill. I am so appreciative for the great people on this board with all of your diverse, rich experience, who tirelessly dig up and report on great new info and present your analysis in ways that even I can understand. - ok, that was a left-over "I am thankful for ..." from Thanksgiving. So, here is a Christmas Kumbaya present for all. Warning, this is not your average hum-drum Kumbaya from The Seekers. Fasten your seatbelt and Check this out. - www.youtube.com/watch?v=stw3osNnEkY&ab_channel=DanielMoraes And while I am at the early X-mas wishes ... ... And a Happy, and Profitable New Year. (I'm still hoping for profitability by 4Q 2021). Come on, Focus, Mike!!! ok, this post was about as weird as that video. I think I might just put PB down til next year. Merry Christmas, all. |
|
